The DOI matches its Crossref record.
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.
Abstract
A series of 33 patients were treated with a four-day continuous infusion of carboplatin in a phase I study to determine the maximum-tolerated dose (MTD) of this agent when used with autologous bone marrow reinfusion. Doses were escalated from 375 to 2,400 mg/m2; autologous bone marrow reinfusion was added to the regimen at doses of 1,600 mg/m2 and above. The MTD was determined to be 2,000 mg/m2. Dose-limiting toxicity consisting of reversible hepatotoxicity, renal dysfunction, and moderate to severe ototoxicity was observed with a dose of 2,400 mg/m2. There were ten responses in 31 heavily pretreated patients, including six responses in 11 patients with recurrent ovarian cancer. Pharmacokinetic studies revealed a systemic clearance (Clss) of 4.5 L/m2/h. This value is consistent with clearances reported for carboplatin administered at lower doses and by different schedules. No evidence for saturation of systemic clearance at higher doses was observed. Carboplatin appears to be an active drug that can undergo considerable dose escalation when used in conjunction with autologous bone marrow support.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs
Müller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2033 · Cited by 878
Müller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., & Galle, P. R. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119174 · Cited by 748
New Cisplatin Analogues in Development: A Review
Weiss, R. B., & Christian, M. C. (1993) · Drugs · doi:10.2165/00003495-199346030-00003 · Cited by 404
Anticancer Drug???Induced Kidney Disorders: Incidence, Prevention and Management
Kintzel, P. E. (2001) · Drug Safety · doi:10.2165/00002018-200124010-00003 · Cited by 355
Metadata
- Authors
- Shea, T. C., Flaherty, M., Elias, A., Eder, J. P., Antman, K., Begg, C., Schnipper, L., Frei, E., & Henner, W. D.
- Venue
- Journal of Clinical Oncology
- Published
- 1989-05
- Volume
- 7
- Issue
- 5
- Pages
- 651-661
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2135001035
- Cited by
- 188
- References
- 0
- FWCI
- 18.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. https://app.cochat.ai/papers/10.1200/jco.1989.7.5.651
- The paper
- Shea, T. C., Flaherty, M., Elias, A., Eder, J. P., Antman, K., Begg, C., Schnipper, L., Frei, E., & Henner, W. D. (1989). A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1989.7.5.651
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.